ALK-Positive Lung Non-Small Cell Carcinoma

ALK-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05987956	Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms(Drugs-SNPs)	active not recruiting	Phase 2 / Phase 3	600	Medicine Invention Design, IncINDUSTRY	1	Sep 29, 2026	clinicaltrials
NCT04009317	Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)	unknown	Phase 3	260	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY